Zacks Research Analysts Cut Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Zacks Research decreased their FY2025 EPS estimates for ACADIA Pharmaceuticals in a report released on Monday, April 22nd. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.93 per share for the year, down from their prior estimate of $0.94. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.62 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals' Q1 2026 earnings at $0.41 EPS and FY2026 earnings at $1.28 EPS.

Other equities analysts also recently issued reports about the stock. Royal Bank of Canada reduced their target price on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an "outperform" rating for the company in a report on Wednesday, February 28th. Mizuho downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $39.00 to $25.00 in a report on Tuesday, March 12th. Oppenheimer reiterated a "market perform" rating and issued a $25.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, February 5th. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 28th. Finally, JMP Securities restated a "market outperform" rating and set a $42.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, ACADIA Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $35.82.

ACADIA Pharmaceuticals Stock Down 1.5 %

Shares of ACAD stock traded down $0.25 on Tuesday, hitting $16.74. The stock had a trading volume of 1,476,023 shares, compared to its average volume of 1,773,102. The business has a 50 day moving average price of $20.64 and a 200 day moving average price of $23.72. The company has a market cap of $2.76 billion, a PE ratio of -44.05 and a beta of 0.37. ACADIA Pharmaceuticals has a one year low of $16.60 and a one year high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.04). The firm had revenue of $231.04 million during the quarter, compared to the consensus estimate of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The business's revenue was up 69.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.26) earnings per share.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, CEO Stephen Davis sold 26,574 shares of the company's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $17.87, for a total value of $474,877.38. Following the sale, the chief executive officer now owns 144,267 shares in the company, valued at approximately $2,578,051.29. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, COO Brendan Teehan sold 2,568 shares of the company's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $17.87, for a total transaction of $45,890.16. Following the completion of the transaction, the chief operating officer now directly owns 38,796 shares of the company's stock, valued at approximately $693,284.52. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Stephen Davis sold 26,574 shares of the company's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $17.87, for a total value of $474,877.38. Following the transaction, the chief executive officer now directly owns 144,267 shares of the company's stock, valued at $2,578,051.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,383 shares of company stock worth $1,291,362. Corporate insiders own 27.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Empire Life Investments Inc. raised its stake in ACADIA Pharmaceuticals by 0.3% in the 4th quarter. Empire Life Investments Inc. now owns 174,815 shares of the biopharmaceutical company's stock valued at $5,473,000 after purchasing an additional 467 shares during the last quarter. Handelsbanken Fonder AB raised its stake in ACADIA Pharmaceuticals by 2.3% in the 4th quarter. Handelsbanken Fonder AB now owns 31,633 shares of the biopharmaceutical company's stock valued at $990,000 after purchasing an additional 700 shares during the last quarter. Franklin Resources Inc. raised its stake in ACADIA Pharmaceuticals by 1.6% in the 4th quarter. Franklin Resources Inc. now owns 50,405 shares of the biopharmaceutical company's stock valued at $1,578,000 after purchasing an additional 803 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth $39,000. Finally, Phocas Financial Corp. increased its stake in shares of ACADIA Pharmaceuticals by 1.9% in the 4th quarter. Phocas Financial Corp. now owns 66,957 shares of the biopharmaceutical company's stock worth $2,096,000 after acquiring an additional 1,266 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.